Literature DB >> 10489623

Molecular precursor lesions in oesophageal cancer.

R Montesano1, P Hainaut.   

Abstract

Oesophageal cancer is the fifth most frequent cause of cancer death world wide and most of these cancers occur in developing countries. The survival rate for SCC or ADCs of the oesophagus is equally poor, mainly due to their late detection and the poor efficacy of the therapy. A short review of the natural history of these cancers, and in particular the occurrence of genetic and cellular alterations associated with cancer progression, is presented and discussed in the context of the relevance to aetiology and pathogenesis. SCCs and ADCs show a distinct pattern of TP53 mutations, namely a high prevalence of G > A transitions at CpG sites in ADCs whereas in SCCs a higher prevalence of G to T transversions and mutations at A:T base pairs is present. In both types of cancers TP53 mutations occur very early and are followed by the accumulation of other genetic alterations during the process of oesophageal carcinogenesis. The value of these genetic alterations in assessing the multifocal monoclonal origin of oesophageal cancer is also addressed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10489623

Source DB:  PubMed          Journal:  Cancer Surv        ISSN: 0261-2429


  4 in total

Review 1.  TP53 mutations in human cancers: origins, consequences, and clinical use.

Authors:  Magali Olivier; Monica Hollstein; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

2.  Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia.

Authors:  P Tanière; G Martel-Planche; D Maurici; C Lombard-Bohas; J Y Scoazec; R Montesano; F Berger; P Hainaut
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

Review 3.  Methylation in esophageal carcinogenesis.

Authors:  Da-Long Wu; Feng-Ying Sui; Xiao-Ming Jiang; Xiao-Hong Jiang
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

4.  Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma.

Authors:  Byeong-Bae Park; Young-Hyuck Im; In Gyu Hwang; Sang Cheol Lee; Jin Seok Ahn; Myung-Ju Ahn; Ho-Yeong Lim; Won Ki Kang; Keunchil Park
Journal:  Invest New Drugs       Date:  2008-03-27       Impact factor: 3.850

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.